文献速递主动脉疾病

马凡综合征患者主动脉病变的血管内治疗:单中心经验

Endovascular Treatment of Aortic Pathologies in Patients With Marfan Syndrome: Single-Center Experience.
PubMed 文献 · J Endovasc Ther · 2021-12-30

单中心回顾性分析2010年1月至2020年5月连续24例马凡综合征(MFS)患者因主动脉病变接受血管内修复或杂交手术的结果;作者认为血管内治疗在MFS主动脉病变患者中看似可行,早期和中期死亡率与再干预率可接受。

要点

  • 24例MFS患者中,胸主动脉腔内修复12例(50%),杂交手术7例(29%),分支/开窗腔内修复4例(17%)。
  • 中位随访42个月,24个月累积生存率87%,12个月免于再干预率77%。

核心结论

  • 作者结论认为,MFS患者主动脉病变的血管内治疗在死亡率和再干预率方面看似可行,早期和中期结果可接受,血管内治疗在MFS主动脉病变患者中扮演着日益增加的角色。

研究设计与样本

  • 单中心回顾性分析,连续纳入2010年1月至2020年5月因主动脉病变接受血管内修复或杂交手术的MFS患者24例,中位年龄48(13-78)岁,男性58%。

主要发现

  • 干预指征:慢性主动脉夹层伴动脉瘤样变16例(67%)、急性B型主动脉夹层4例(17%)、无夹层的主动脉瘤3例(13%)、主动脉壁内血肿1例(4%)。
  • 多数患者无症状(83%),有症状3例(13%),局限性破裂1例(4%);中位动脉瘤直径56(35-86)mm。
  • 手术方式:胸主动脉腔内修复12例(50%)、开窗或分支腔内主动脉修复4例(17%)、髂动脉覆膜支架置入1例(4%)、杂交手术7例(29%);分期手术12例(50%)。
  • 中位随访42(1-127)个月,24个月累积生存率87%,12个月免于再干预率77%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the outcome of endovascular treatment of aortic pathologies in patients with Marfan syndrome (MFS) at a single institution. METHODS: Consecutive MFS patients who underwent endovascular repair or hybrid procedures for aortic pathologies from January 2010 to May 2020 were identified. Several endovascular and hybrid strategies have been used. Technical success, short- and mid-term survival, complications, and re-interventions were retrospectively analyzed. RESULTS: During the study period, 24 patients with MFS (median age, 48 [13-78] years; 58% males) were treated. Indications for intervention were chronic aortic dissection with aneurysm degeneration in 16 patients (67%), acute type B aortic dissection in 4 patients (17%), aortic aneurysm without any dissection in 3 patients (13%), and aortic intramural hematoma in 1 patient (4%). Most patients were asymptomatic (83%), three (13%) were symptomatic and one (4%) had a contained rupture. The median aneurysm diameter was 56 (35-86) mm. Hybrid procedures were performed in 7 (29%) patients. Thoracic endovascular repair was performed in 12 (50%) patients, a fenestrated or branched endovascular aortic repair in 4 (17%) patients, and placement of an iliac artery stent-graft in 1 (4%) patient. Procedures were staged in 12 (50%) patients. Technical success was achieved in all patients. The median intensive care unit stay was 6 (range, 1-30) days, and the median hospital stay was 23 (range, 3-112) days. Early mortality was reported in 1 (4%) patient. Wound infection was seen in 7 (29%) patients and gastrointestinal complications in 3 (13%) patients. The median follow-up was 42 (range, 1-127) months. The cumulative survival rate was 87% at 24 months. The cumulative freedom from re-intervention was 77% at 12 months. CONCLUSIONS: Endovascular treatment of aortic pathologies in patients with MFS appears feasible with acceptable early and mid-term outcomes in terms of mortality and re-intervention rates. Endovascular therapy plays an increasing role in MFS patients with aortic pathology.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Kölbel T, Eleshra A, Aldag M, et al. Endovascular Treatment of Aortic Pathologies in Patients With Marfan Syndrome: Single-Center Experience. J Endovasc Ther. 2021. PMID: 34969304. doi:10.1177/15266028211067733

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。